Real-world effectiveness of stroke prevention in patients with non-valvular atrial fibrillation treated with rivaroxaban vs. phenprocoumon in Germany - insights from the reload study

被引：0
|
作者：
Bonnemeier, H. [1 ]
Mundhenke, M. [2 ]
Von Mach, T. [2 ]
Huelsebeck, M. [2 ]
机构：
[1] Univ Med Ctr Schleswig Holstein, Dept Electrophysiol & Rhythmol, Kiel, Germany
[2] Bayer Vital GmbH, Leverkusen, Germany
来源：
EUROPEAN HEART JOURNAL | 2017年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P3581
引用
收藏
页码：765 / 765
页数：1
相关论文
共 50 条
  • [21] XANAP: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia
    Kim, Young-Hoon
    Shim, Jaemin
    Tsai, Chia-Ti
    Wang, Chun-Chieh
    Vilela, Gilbert
    Muengtaweepongsa, Sombat
    Kurniawan, Mohammad
    Maskon, Oteh
    Hsu, Li Fern
    Thang Huy Nguyen
    Thanachartwet, Thititat
    Sim, Kenneth
    Camm, A. John
    JOURNAL OF ARRHYTHMIA, 2018, 34 (04) : 418 - 427
  • [22] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS RIVAROXABAN FOR PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN SPAIN
    Canal Fontcuberta, G.
    Escolar Albaladejo, G.
    Betegon Nicolas, L.
    de Salas-Cansado, M.
    Rubio-Rodriguez, D.
    Rubio-Terres, G.
    VALUE IN HEALTH, 2013, 16 (07) : A523 - A523
  • [23] Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system
    Villines, Todd C.
    Ahmad, Azhar
    Petrini, Michaela
    Tang, Wenbo
    Evans, Amber
    Rush, Toni
    Thompson, David
    Oh, Kelly
    Schwartzman, Eric
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2019, 5 (02) : 80 - 90
  • [24] The management of anticoagulant treatment in non-valvular atrial fibrillation real-world patients
    Valeriani, Emanuele
    Ageno, Walter
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2019, 62 : 7 - 8
  • [25] STROKE PROPHYLAXIS MANAGEMENT STRATEGIES IN NON-VALVULAR ATRIAL FIBRILLATION (NVAF) PATIENTS: A REAL-WORLD EXPERIENCE
    Siddiqui, Safia
    Davis, Karrie
    Heard, Thomas
    Glover, Jon
    Hartman, Timothy
    Patel, Amar
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1505 - 1505
  • [26] A Real-World, Prospective, Observational Study of Rivaroxaban on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-Valvular Atrial Fibrillation: XARENAL
    Oh, Il-Young
    Lee, Chang Hoon
    Choi, Eue-Keun
    Lim, Hong Euy
    Oh, Yong-Seog
    Choi, Jong-Il
    Ahn, Min-Soo
    Kim, Ju Youn
    Kim, Nam-Ho
    Yoon, Namsik
    Sandmann, Martin
    Choi, Kee-Joon
    KOREAN CIRCULATION JOURNAL, 2025, 55 (02) : 121 - 131
  • [27] Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
    Tepper, Ping G.
    Mardekian, Jack
    Masseria, Cristina
    Phatak, Hemant
    Kamble, Shital
    Abdulsattar, Younos
    Petkun, William
    Lip, Gregory Y. H.
    PLOS ONE, 2018, 13 (11):
  • [28] Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation
    Yuji Murakawa
    Takanori Ikeda
    Satoshi Ogawa
    Takanari Kitazono
    Jyoji Nakagawara
    Kazuo Minematsu
    Susumu Miyamoto
    Yasuhiro Hayashi
    Yoko Kidani
    Yutaka Okayama
    Toshiyuki Sunaya
    Shoichiro Sato
    Satoshi Yamanaka
    Heart and Vessels, 2020, 35 : 1125 - 1134
  • [29] The effectiveness of oral anticoagulants in the prevention of stroke in patients with non-valvular atrial fibrillation: results from the Stroke Prevention and Anticoagulants (SPA) study
    Grimaldi-Bensouda, L.
    Le Heuzey, J. Y.
    Ferrieres, J.
    Leys, D.
    Davy, J. M.
    Martinez, M.
    Smadja, D.
    Ellie, E.
    Sablot, D.
    Nighoghossian, N.
    Benichou, J.
    Touze, E.
    Abenhaim, L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2018, 32 : 29 - 29
  • [30] Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis
    de Jong, Lisa Aniek
    Gout-Zwart, Judith J.
    van den Bosch, Marina
    Koops, Mike
    Postma, Maarten J.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 306 - 318
12345